Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
Werewolf Therapeutics (NASDAQ: HOWL) announced its participation in the Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit in Boston on May 15-16, 2025. Dr. Sameer Chopra, VP of Clinical Development, will present on May 15 at 4:15 PM ET, discussing "Tumor-activated INDUKINE Molecules: Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer Immunotherapy." The presentation will showcase data from first-in-human clinical trials of IL-2 and IL-12 INDUKINE molecules, which have validated the company's approach to developing conditionally activated therapeutics for cancer treatment.
Werewolf Therapeutics (NASDAQ: HOWL) ha annunciato la sua partecipazione al 6° Summit Annuale sullo Sviluppo di Farmaci a Base di Citochine di Hanson Wade, che si terrà a Boston il 15 e 16 maggio 2025. Il dottor Sameer Chopra, vicepresidente dello sviluppo clinico, presenterà il 15 maggio alle 16:15 ET, con un intervento dal titolo "Molecole INDUKINE attivate dal tumore: migliorare l'indice terapeutico delle citochine proinfiammatorie per l'immunoterapia oncologica." La presentazione mostrerà i dati dei primi trial clinici sull'uomo delle molecole INDUKINE IL-2 e IL-12, che hanno confermato l'approccio dell'azienda nello sviluppo di terapie condizionalmente attivate per il trattamento del cancro.
Werewolf Therapeutics (NASDAQ: HOWL) anunció su participación en la 6ª Cumbre Anual sobre Desarrollo de Fármacos Basados en Citoquinas de Hanson Wade, que se llevará a cabo en Boston los días 15 y 16 de mayo de 2025. El Dr. Sameer Chopra, vicepresidente de desarrollo clínico, presentará el 15 de mayo a las 4:15 PM ET, con una charla titulada "Moléculas INDUKINE activadas por tumores: mejorando el índice terapéutico de las citoquinas proinflamatorias para la inmunoterapia contra el cáncer." La presentación mostrará datos de los primeros ensayos clínicos en humanos con las moléculas INDUKINE IL-2 e IL-12, que han validado el enfoque de la compañía para desarrollar terapias condicionalmente activadas para el tratamiento del cáncer.
Werewolf Therapeutics (NASDAQ: HOWL)는 2025년 5월 15일부터 16일까지 보스턴에서 열리는 Hanson Wade 제6회 연례 사이토카인 기반 약물 개발 서밋에 참가한다고 발표했습니다. 임상개발 부사장인 Dr. Sameer Chopra는 5월 15일 오후 4시 15분(동부시간)에 "종양 활성화 INDUKINE 분자: 암 면역치료를 위한 염증성 사이토카인의 치료 지수 향상"이라는 주제로 발표할 예정입니다. 이번 발표에서는 IL-2와 IL-12 INDUKINE 분자의 최초 인간 임상시험 데이터를 소개하며, 암 치료를 위한 조건부 활성화 치료제 개발에 대한 회사의 접근법을 입증할 것입니다.
Werewolf Therapeutics (NASDAQ : HOWL) a annoncé sa participation au 6e Sommet Annuel sur le Développement de Médicaments à Base de Cytokines de Hanson Wade, qui se tiendra à Boston les 15 et 16 mai 2025. Le Dr Sameer Chopra, vice-président du développement clinique, présentera le 15 mai à 16h15 (heure de l'Est), avec une intervention intitulée « Molécules INDUKINE activées par la tumeur : améliorer l’indice thérapeutique des cytokines pro-inflammatoires pour l’immunothérapie du cancer. » La présentation mettra en avant des données issues des premiers essais cliniques chez l'humain des molécules INDUKINE IL-2 et IL-12, validant ainsi l’approche de la société dans le développement de traitements conditionnellement activés pour le cancer.
Werewolf Therapeutics (NASDAQ: HOWL) gab seine Teilnahme am 6. jährlichen Hanson Wade Cytokine-Based Drug Development Summit bekannt, der am 15. und 16. Mai 2025 in Boston stattfindet. Dr. Sameer Chopra, Vizepräsident für klinische Entwicklung, wird am 15. Mai um 16:15 Uhr ET einen Vortrag halten mit dem Thema „Tumoraktivierte INDUKINE-Moleküle: Verbesserung des therapeutischen Index proinflammatorischer Zytokine für die Krebsimmuntherapie.“ Die Präsentation wird Daten aus den ersten klinischen Studien am Menschen mit IL-2- und IL-12-INDUKINE-Molekülen vorstellen, die den Ansatz des Unternehmens zur Entwicklung bedingt aktivierter Therapeutika für die Krebsbehandlung bestätigt haben.
- None.
- None.
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Development Summit taking place May 15-16 in Boston, Massachusetts.
The presentation will highlight how data from patients treated with IL-2 and IL-12 INDUKINE molecules in first-in-human clinical trials have successfully validated Werewolf’s unique approach to engineering differentiated, tumor-activated immunotherapies. Additional details are below.
Topic: Tumor-activated INDUKINE Molecules: Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer Immunotherapy
Date: Thursday, May 15, 2025
Time: 4:15pm ET
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
FAQ
What will Werewolf Therapeutics (HOWL) present at the 2025 Cytokine Summit?
Who will be presenting for Werewolf Therapeutics at the 2025 Cytokine Summit?
When and where is Werewolf Therapeutics' presentation at the Cytokine Summit?
What is the focus of Werewolf Therapeutics' INDUKINE technology?
